RNA Outsourcing Articles

  1. 4 Risk Mitigation Strategies For mRNA Production 4/17/2023

    Planning and procuring custom materials needed to manufacture mRNA remains a top concern. This article shares risk mitigation strategies for multi-sourcing, S&OP process, packaging size, and material expiry.

  2. Moderna's Global mRNA Manufacturing Strategy: A Closer Look 3/27/2023

    In part 2 of this 3-part series, I argue Moderna’s strategy for scaling its mRNA vaccine manufacturing paradigm globally is one of the best examples the ATMP space has today of what it means to begin with and keep the end in mind.

  3. Moderna And The Building Of Bridge Facilities 2/27/2023

    In August of 2021, relatively overlooked because of other news swirling around our industry, Moderna became the anchor client in a new cleanroom on demand housed in a bridge facility in Massachusetts. In retrospect, it may have legitimized a new era in outsourcing.

  4. Defining The RNA Therapeutics Industry In 2023 1/16/2023

    Four executives outline which industry challenges, strategic considerations, and opportunities should be top of mind as RNA therapeutics companies establish their to-do lists for 2023.

  5. Biomanufacturing Capacity Crunch: It's The Supply Chain's Fault 10/7/2022

    What's behind the protracted biopharma manufacturing capacity crunch, when will it end, and what are manufacturers doing to keep supply on track? During Biotech Week in Boston ad BioProcess International, CDMOs and sponsors weighed in.

  6. How Can We Move RNA Forward In Our Therapeutics Arsenal? 7/18/2022

    RNA technologies, including mRNA therapeutics, have emerged as a promising drug modality. However, they have unique challenges. BioPhorum has dedicated a team to investigate these challenges and this Q&A shares their practical considerations for how to move this field forward.